Irreversible MK2 Kinase Inhibitors with Covalent Warhead Groups
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in effectively targeting and inhibiting MK2 kinases, which are involved in various inflammatory and chronic diseases, such as rheumatoid arthritis and inflammatory bowel disease, due to the lack of specific and potent inhibitors.
Innovation Solution
Development of irreversible inhibitors of MK2 kinase, specifically compounds with a warhead group that covalently binds to cysteine residues in the kinase's binding domain, thereby irreversibly inhibiting the enzyme and modulating its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to target MK2 kinases, then treatment is provided for inflammatory and chronic diseases, but the agents are inadequate in effectively inhibiting MK2 kinase activity due to lack of specific and potent inhibitors
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features (warhead groups, heteroaryl rings, and substituent patterns) that target particular regions of the MK2 kinase binding domain. The compounds are engineered to interact with specific amino acid residues in the ATP-binding pocket, providing localized and selective inhibition of MK2 activity while maintaining therapeutic effectiveness for inflammatory and chronic diseases.
2Reliability
If irreversible inhibitors with warhead groups are developed to covalently bind to cysteine residues, then potent and specific MK2 inhibition is achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a warhead group (containing reactive atoms like carbon, nitrogen, or oxygen for covalent bonding to cysteine residues), a heteroaryl ring system (providing structural framework and additional binding interactions), and specific substituent groups (R1-R6) that fine-tune binding affinity and selectivity. This modular segmentation allows for systematic optimization of potency while managing structural complexity through defined functional regions.
3Reliability
If compounds with multiple substituent groups and heteroaryl rings are synthesized to improve MK2 binding affinity, then inhibition efficacy increases, but the difficulty of synthesis and manufacturing increases
Solution Approach 1:
The patent applies universality by designing a core heteroaryl ring structure (including pyrrole, imidazole, triazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, and their fused ring systems) that serves multiple functions: providing a planar binding surface for MK2 interaction, offering heteroatoms for hydrogen bonding, and allowing systematic substitution at multiple positions (R1-R6) to optimize affinity. This universal core structure simplifies manufacturing by using a common scaffold that can be modified through standard organic synthesis techniques to produce various high-affinity inhibitors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds effectively inhibit MK2 kinase activity, providing a potential therapeutic approach for treating diseases associated with abnormal cellular responses, including inflammatory and chronic conditions by specifically targeting and modulating the kinase's function.
Implementation Method 1
compounds with a warhead group that covalently binds to cysteine residues in the kinase's binding domain, thereby irreversibly inhibiting the enzyme
Data Source
AI summary
The present invention provides compounds of formula V:or pharmaceutically acceptable salts thereof, useful as inhibitors of MK2 kinases, compositions thereof, and methods of using the same.